Table 2.
Results of drug sensitivity tests for the pathogen.
| Drug sensitivity | Sensitivity | MIC |
|---|---|---|
| Ticarcillin/Clavulanic acid | I | 32 |
| Aminotrans | S | 4 |
| Meropenem | S | <0.25 |
| Tobramycin | I | 8 |
| Ciprofloxacin | R | >4.0 |
| Doxycycline | S | <0.5 |
| Mucomycin (polymyxin B) | S | ≤ 0.5 |
| Minocycline | R | >1.0 |
| ESBL | + | |
| Amoxicillin Clavulanate Potassium | S | 8 |
| Piperacillin sulbactam | S | <4.0 |
| Cefuroxime | R | >64 |
| Cefuroxime | R | >64 |
| Cefoxitin | S | <4.0 |
| Ceftazidime | S | 0.5 |
| Ceftriaxone | R | >64 |
| Cefoperazone sodium sulbactam sodium | S | 16 |
| Cefepime | R | >64 |
| Ertapenem | S | <0.12 |
| Imipenem | S | <0.25 |
| Amikacin | S | <0.2 |
| Levofloxacin | R | >8.0 |
| Tigecycline | S | <0.5 |
| Cotrimoxazole | S | <20 |
MIC, Minimum inhibition concentration. The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) standard M100-S29 (CLSI, 2021). Isolates were first identified and Antimicrobial Susceptibility Test by Vitek 2 Compact, further identification using MALDI-TOF MS (Vitek MS, BioMe ìrieux, France).